Schainuck LI, Fouty R, Cutler RE. Emphysematous pyelonephritis. A new case and review of previous observations. Am J Med. 1968;44:134–9.

Article  CAS  PubMed  Google Scholar 

Olvera-Posada D, Armengod-Fischer G, Vázquez-Lavista LG, Maldonado-Ávila M, Rosas-Nava E, Manzanilla-García H, et al. Emphysematous pyelonephritis: multicenter clinical and therapeutic experience in Mexico. Urology. 2014;83:1280–4.

Article  PubMed  Google Scholar 

Rahoui M, Ouanes Y, Chaker K, Bibi M, Dali KM, Sellami A, et al. Predictive factors for failure of conservative management in patients with emphysematous pyelonephritis. Ann Med Surg (Lond). 2022;78: 103930.

PubMed  Google Scholar 

Japanese Association for Infectious Disease/Japanese Society of Chemotherapy; JAID/JSC Guide/Guidelines to Clinical Management of Infectious Disease Preparing Committee; Urinary tract infection/male genital infection working group, Shingo Y, Kiyohito I, Hiroshi H, Tadahiro N, Isao M, Tadashi H, et al. JAID/JSC Guidelines for clinical management of infectious disease 2015 - urinary tract infection/male genital infection. J Infect Chemother. 2017;23(11):733–51.

Article  Google Scholar 

Huang JJ, Tseng CC. Emphysematous pyelonephritis: clinicoradiological classification, management, prognosis, and pathogenesis. Arch Intern Med. 2000;160:797–805.

Article  CAS  PubMed  Google Scholar 

Ahlering TE, Boyd SD, Hamilton CL, Bragin SD, Chandrasoma PT, Lieskovsky G, et al. Emphysematous pyelonephritis: a 5-year experience with 13 patients. J Urol. 1985;134:1086–8.

Article  CAS  PubMed  Google Scholar 

Wan YL, Lee TY, Bullard MJ, Tsai CC. Acute gas-producing bacterial renal infection: correlation between imaging findings and clinical outcome. Radiology. 1996;198:433–8.

Article  CAS  PubMed  Google Scholar 

Soulen MC, Fishman EK, Goldman SM, Gatewood OM. Bacterial renal infection: role of CT. Radiology. 1989;171:703–7.

Article  CAS  PubMed  Google Scholar 

Expert Panel on Urologic Imaging, Nikolaidis P, Dogra VS, Goldfarb S, Gore JL, Harvin HJ, Heilbrun ME, et al. ACR appropriateness Criteria® acute pyelonephritis. J Am Coll Radiol. 2018;15:S232–9.

Article  Google Scholar 

Bonkat G, Bartoletti R, Bruyère F, Cai T, Geerlings SE, Köves B, et al. European Association of Urology 2022 guidelines on urological infections. https://uroweb.org/guidelines/urological-infections/summary-of-changes/2022. Accessed 5 Mar 2023.

Owa S, Sasaki K, Yonemura S, Sakurai M. A case of emphysematous pyelonephritis after starting treatment for acute pyelonephritis. Hinyokika Kiyo. 2021;67:373–9.

PubMed  Google Scholar 

Takei T, Hama Y, Ito T, Takemoto M. Emphysematous pyelonephritis detected incidentally by a second CT examination after the improvement of septic shock. Nihon Shuchu Chiryo Igakukai Zasshi. 2009;16:487–91.

Article  Google Scholar 

Somani BK, Nabi G, Thorpe P, Hussey J, Cook J, N’Dow J. Is percutaneous drainage the new gold standard in the management of emphysematous pyelonephritis? Evidence from a systematic review. J Urol. 2008;179:1844–9.

Article  PubMed  Google Scholar 

Aboumarzouk OM, Hughes O, Narahari K, Coulthard R, Kynaston H, Chlosta P, et al. Emphysematous pyelonephritis: time for a management plan with an evidence-based approach. Arab J Urol. 2014;12:106–15.

Article  PubMed  Google Scholar 

Adapala RR, Shetty R, Venugopal P, Prabhu GGL, Yalla D, Unnikrishnan B. Renal salvage, an achievable goal in patients with emphysematous pyelonephritis: outcomes of an algorithmic renal preserving strategy. Urol Ann. 2020;12:156–62.

Article  PubMed  PubMed Central  Google Scholar 

US Food and Drug Administration. FDA drug safety communication: FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections; updated 2018. https://www.fda.gov/drugs/drug-safety-and-availability/fda-revises-labels-sglt2-inhibitors-diabetes-include-warnings-about-too-much-acid-blood-and-serious. Accessed 21 Oct 2022.

Fisher A, Fralick M, Filion KB, Dell’Aniello S, Douros A, Tremblay E, et al. Sodium-glucose co-transporter-2 inhibitors and the risk of urosepsis: a multi-site, prevalent new-user cohort study. Diabetes Obes Metab. 2020;22:1648–58.

Article  CAS  PubMed  Google Scholar 

Tanvi P, Morgan C, Jesse H, Alamdeep K, Aliza L. Evaluating the safety of sodium-glucose cotransporter-2 inhibitors in a nationwide veterans health administration observational cohort study. Am J Cardiol. 2023;201:281–3.

Article  Google Scholar 

Dave CV, Schneeweiss S, Kim D, Fralick M, Tong A, Patorno E. Sodium-glucose cotransporter-2 inhibitors and the risk for severe urinary tract infections: a population-based cohort study. Ann Intern Med. 2019;171:248–56.

Article  PubMed  PubMed Central  Google Scholar 

Mauro R, Gian PF, Angelo A. Safety of sodium-glucose cotransporter 2 inhibitors in elderly patients with type 2 diabetes: a meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2023. https://doi.org/10.1111/dom.15193.Accessed26Jul.

Article  Google Scholar 

Sarah E, Christine L, Lindsay T. Evaluation of the safety and tolerability of sodium-glucose co-transporter 2 inhibitors in the older population: a systematic review. Sr Care Pharm. 2023;38:276–87.

Article  Google Scholar 

Kufel WD, Scrimenti A, Steele JM. A case of septic shock due to Serratia marcescens pyelonephritis and bacteremia in a patient receiving empagliflozin. J Pharm Pract. 2017;30:672–5.

Article  PubMed  Google Scholar 

Woloshuk A, Lee M, Assmus M, Agarwal D, Krambeck A, Large T. A case of ureteral fungal mass removal in a patient taking empagliflozin. CEN Case Rep. 2021;10:603–7.

Article  PubMed  PubMed Central  Google Scholar 

Vinik AI, Maser RE, Mitchell BD, Freeman R. Diabetic autonomic neuropathy. Diabetes Care. 2003;26:1553–79.

Article  PubMed  Google Scholar